Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Catumaxomab - Neovii Biotech

Drug Profile

Catumaxomab - Neovii Biotech

Alternative Names: Anti-CD3 anti-EpCAM monoclonal antibody; Anti-EpCAM anti-CD3 monoclonal antibody; Removab

Latest Information Update: 01 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TRION Pharma
  • Developer Neovii Biotech; Swedish Orphan Biovitrum; TRION Pharma
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Macrophage stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Gastric cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Market Withdrawal Malignant ascites
  • Discontinued Carcinoma; Gastric cancer; Ovarian cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 25 Sep 2017 Discontinued - Phase-I for Carcinoma in Spain, Denmark and Austria (IV), because not listed on Neovii Biotech's pipeline of September 2017
  • 25 Sep 2017 Discontinued - Phase-II for Gastric cancer (Adjuvant therapy) in Austria, Germany, Spain and United Kingdom (Intraperitoneal), because not listed on Neovii Biotech's pipeline of September 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top